Trends in Serum Creatinine Testing among Commercially Insured Patients with Diagnosed CKD

The prevalence of serum creatinine testing among commercially insured patients with diagnosed CKD increased from 57.0% in 2007 to 77.5% in 2020. The testing rates varied by age, race/ethnicity, sex, and presence of comorbidities like diabetes and hypertension. Older patients had higher testing rates, with disparities noted among different demographic groups. Data analysis over the years reveals insights into healthcare practices for managing CKD in commercially insured populations.

• CKD
• Serum Creatinine
• Testing Rates
• Commercially Insured
• Healthcare Practices

medidoc Follow

Uploaded on Mar 15, 2025 | 0 Views

Download Presentation

Please find below an Image/Link to download the presentation.

The content on the website is provided AS IS for your information and personal use only. It may not be sold, licensed, or shared on other websites without obtaining consent from the author.If you encounter any issues during the download, it is possible that the publisher has removed the file from their server.

You are allowed to download the files provided on this website for personal or commercial use, subject to the condition that they are used lawfully. All files are the property of their respective owners.

The content on the website is provided AS IS for your information and personal use only. It may not be sold, licensed, or shared on other websites without obtaining consent from the author.

Presentation Transcript

1. Trends in Serum Creatinine Testing among Trends in Serum Creatinine Testing among Commercially Insured Patients with Diagnosed CKD Commercially Insured Patients with Diagnosed CKD The prevalence of patients with diagnosed CKD receiving serum creatinine testing was 57.0% in 2007 and 77.5% in 2020, in a commercially insured patient population. Serum creatinine testing tended to be higher among older patients. The prevalence of patients younger than 60 years receiving serum creatinine testing decreased from 2007 to 2020. Hispanic patients tended to have the lowest prevalence of testing. The prevalence of serum creatinine testing tended to be higher for patients with diabetes than without diabetes. Patients with hypertension were approximately 1.5 times as likely to receive serum creatinine testing than those without hypertension across this time period. Data Source: Clinformatics Commercial https://nccd.cdc.gov/CKD/detail.aspx?Qnum=Q786

2. Trends in Serum Creatinine Testing among Commercially Trends in Serum Creatinine Testing among Commercially Insured Patients with Diagnosed CKD, Overall Insured Patients with Diagnosed CKD, Overall 90 Serum Creatinine Testing (%) 80 70 60 50 40 30 20 10 0

3. Trends in Serum Creatinine Testing among Commercially Trends in Serum Creatinine Testing among Commercially Insured Patients with Diagnosed CKD, by Age Insured Patients with Diagnosed CKD, by Age 90 Serum Creatinine Testing (%) 80 70 60 50 40 30 20 10 0 Overall 20 29 years 30 39 years 40 49 years 50 59 years 60 69 years 70+ years

4. Trends in Serum Creatinine Testing among Commercially Trends in Serum Creatinine Testing among Commercially Insured Patients with Diagnosed CKD, by Sex Insured Patients with Diagnosed CKD, by Sex 100 Serum Creatinine Testing (%) 80 60 40 20 0 Overall Female Male

5. Trends in Serum Creatinine Testing among Commercially Trends in Serum Creatinine Testing among Commercially Insured Patients with Diagnosed CKD, by Race/Ethnicity Insured Patients with Diagnosed CKD, by Race/Ethnicity 100 Serum Creatinine Testing (%) 80 60 40 20 0 Overall Asian Hispanic Black White Unknown

6. Trends in Serum Creatinine Testing among Commercially Trends in Serum Creatinine Testing among Commercially Insured Patients with Diagnosed CKD, by CKD Stage Insured Patients with Diagnosed CKD, by CKD Stage 100 Serum Creatinine Testing (%) 80 60 40 20 0 Overall CKD Stage 1 CKD Stage 2 CKD Stage 3 CKD Stage 4 CKD Stage 5 Unknown

7. Trends in Serum Creatinine Testing among Commercially Trends in Serum Creatinine Testing among Commercially Insured Patients with Diagnosed CKD, by Diabetes Insured Patients with Diagnosed CKD, by Diabetes 100 Serum Creatinine Testing (%) 80 60 40 20 0 Overall With Diabetes Without Diabetes

8. Trends in Serum Creatinine Testing among Commercially Trends in Serum Creatinine Testing among Commercially Insured Patients with Diagnosed CKD, by Hypertension Insured Patients with Diagnosed CKD, by Hypertension 100 Serum Creatinine Testing (%) 80 60 40 20 0 Overall With Hypertension Without Hypertension